Catalyst Dossier · compiled by CeliA 🧫

Eisai (ESALY)

Healthcare · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-03 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

The catalyst path

2026-12-03 (est.)Phase 2 · Lecanemabimp 7/10
2026-12-03 (est.)Phase 2 · E2814imp 7/10
2027-02-14 (est.)Phase 2 · E2086imp 7/10
2027-03-31 (est.)Phase 2 · E7389-LFimp 7/10
2027-03-31 (est.)Phase 2 · Doxorubicinimp 7/10
2027-04-06 (est.)Phase 2 · Perampanel Oral Suspensionimp 7/10

Pipeline

Asset	Phase	Indication
E7389-LF	Phase 2	Solid Neoplasms
Teprenone	Phase 3	Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
T-614	Phase 3	Rheumatoid Arthritis
Eszopiclone 1 mg	Phase 3	Primary Insomnia
E7080 capsule	Phase 2	Thyroid Cancer
Eperisone hydrochloride and Diclofenac sodium	Phase 3	Acute Musculoskeletal Spasm Due to Low Back Pain
Clevudine	Phase 3	Chronic Hepatitis B
Eszopiclone 1 mg- Elderly	Phase 3	Insomnia
BOTULINUM TOXIN TYPE B	Phase 2	Cervical Dystonia
Donepezil 5 mg	Phase 3	Dementia With Lewy Bodies (DLB)
E2020-Donepezil hydrochloride	Phase 2	Down Syndrome
methylcobalamin	Phase 3	Amyotrophic Lateral Sclerosis
E7777	Phase 2	Peripheral T-cell Lymphoma
Rabeprazole sodium, 5 mg Tablets	Phase 2	Healthy
E7090	Phase 2	Cholangiocarcinoma
E5555 50 mg	Phase 2	Coronary Artery Disease
E7389 (Eribulin Mesylate)	Phase 3	HER2-Negative Breast Cancer
menatetranone	Phase 3	Postmenopausal Osteoporosis
Tazemetostat	Phase 2	Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Dotinurad	Phase 3	Gout

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ESALY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.